LDHA and breast carcinoma: In addition, a few clinical trials are evaluating the effectiveness of treatment on the expression of CSC markers, mainly measuring the activity of ALDH, including breast cancer (clinical trial numbers: NCT00949013, NCT01190345, NCT01688609, NCT04142892, NCT01077453, NCT01426880), lung cancer (NCT04634630), lymphoma (NCT00369681), gynecological tumours (NCT02903771), and prostate cancer (NCT03410030) (Table 2).